{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:51:42Z","timestamp":1790621502945,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014935","name":"Biocryst Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.anai.2025.12.011","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T07:24:16Z","timestamp":1766215456000},"page":"322-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema"],"prefix":"10.1016","volume":"136","author":[{"given":"Courtney","family":"Olson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Poulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lopez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nestler-Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Soteres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0001","first-page":"28","article-title":"Diagnosis and management of hereditary angioedema","volume":"111","author":"Johnston","year":"2011","journal-title":"J Am Osteopath Assoc"},{"issue":"7","key":"10.1016\/j.anai.2025.12.011_bib0002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: an update on causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0003","first-page":"48","article-title":"Hereditary angioedema: a review","volume":"121","author":"Zafra","year":"2022","journal-title":"WMJ"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0004","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","article-title":"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review","volume":"19","author":"Guan","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.anai.2025.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/biom14101298","article-title":"Unveiling the complexities of hereditary angioedema","volume":"14","author":"Tutunaru","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.anai.2025.12.011_bib0006","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2147\/PPA.S100383","article-title":"Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema","volume":"10","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2025.12.011_bib0007","doi-asserted-by":"crossref","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.anai.2025.12.011_bib0008","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2340\/00015555-2014","article-title":"Burden of illness in hereditary angioedema: a conceptual model","volume":"95","author":"Bygum","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.anai.2025.12.011_bib0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","article-title":"The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression","volume":"31","author":"Lumry","year":"2010","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","article-title":"The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe","volume":"35","author":"Caballero","year":"2014","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2013.05.028","article-title":"Depression and anxiety in patients with hereditary angioedema","volume":"112","author":"Fouche","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.12.011_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1750-1172-9-99","article-title":"Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe","volume":"9","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"10.1016\/j.anai.2025.12.011_bib0013","first-page":"S308","article-title":"Economic burden limiting proper healthcare delivery, management, and improvement of patient outcomes","volume":"24","author":"Cardarelli","year":"2018","journal-title":"Am J Manag Care"},{"issue":"3","key":"10.1016\/j.anai.2025.12.011_bib0014","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.anai.2020.10.009","article-title":"Current medical management of hereditary angioedema: follow-up survey of US physicians","volume":"126","author":"Riedl","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/ACI.0000000000000992","article-title":"Hereditary angioedema: current therapeutic management and future approaches","volume":"24","author":"Lamacchia","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.12.011_bib0016","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ACI.0000000000001042","article-title":"Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches","volume":"24","author":"Costanzo","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.12.011_bib0017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The international\/Canadian hereditary angioedema guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0018","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2025.12.011_bib0019","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2017.05.017","article-title":"Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States","volume":"119","author":"Riedl","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.12.011_bib0021","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2500\/aap.2021.42.210017","article-title":"Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs","volume":"42","author":"Riedl","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.anai.2025.12.011_bib0022","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.anai.2025.12.011_bib0023","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.iac.2024.03.009","article-title":"Current and emerging therapeutics in hereditary angioedema","volume":"44","author":"Do","year":"2024","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.anai.2025.12.011_bib0024","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","article-title":"US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency","volume":"1","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.12.011_bib0025","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2013.03.034","article-title":"A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema","volume":"131","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.12.011_bib0026","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.anai.2018.07.025","article-title":"Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency","volume":"121","author":"Craig","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.12.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.859","article-title":"Understanding the impact of long-term prophylaxis switches for patients with hereditary angioedema","volume":"153","author":"Dorman","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0028","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.anai.2023.11.016","article-title":"Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat","volume":"132","author":"Riedl","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.12.011_bib0029","article-title":"The current situation of hereditary angioedema patients in Germany: results of an online survey","volume":"10","author":"Magerl","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2025.12.011_bib0031","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40629-022-00223-8","article-title":"Expert consensus on prophylactic treatment of hereditary angioedema","volume":"31","author":"Greve","year":"2022","journal-title":"Allergo J Int"},{"issue":"5","key":"10.1016\/j.anai.2025.12.011_bib0032","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2500\/aap.2022.43.220050","article-title":"Shared decision-making in the management of hereditary angioedema: an analysis of patient and physician perspectives","volume":"43","author":"Riedl","year":"2022","journal-title":"Allergy Asthma Proc"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.12.011_bib0033","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2500\/aap.2020.41.200057","article-title":"Hereditary angioedema and shared decision making","volume":"41","author":"Settipane","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.anai.2025.12.011_bib0034","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2500\/aap.2024.45.240071","article-title":"The utility of shared decision making in the management of hereditary angioedema","volume":"45","author":"Odin","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2025.12.011_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer Adherence"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.12.011_bib0036","article-title":"Jankowska-Polanska B. Treatment satisfaction and pharmacological adherence in patients with chronic diseases","volume":"21","author":"Swiatoniowska-Lonc","year":"2022","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0037","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","article-title":"Hereditary angioedema patients would prefer newer-generation oral prophylaxis","volume":"10","author":"Geba","year":"2021","journal-title":"J Drug Assess"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0038","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13223-021-00550-5","article-title":"Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy","volume":"17","author":"Anderson","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0039","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.anai.2025.12.011_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40271-024-00672-z","article-title":"Pretesting discrete-choice experiments: a guide for researchers","volume":"17","author":"Campoamor","year":"2024","journal-title":"Patient"},{"issue":"7","key":"10.1016\/j.anai.2025.12.011_bib0041","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review","volume":"24","author":"Soekhai","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.anai.2025.12.011_bib0042","unstructured":"US Food and Drug Administration. Incorporating voluntary patient preference information over the total product life cycle: draft guidance for industry, Food and Drug Administration staff, and other interested parties. Accessed November 15, 2024. Available at: https:\/\/www.fda.gov\/media\/181509\/download"},{"key":"10.1016\/j.anai.2025.12.011_bib0043","unstructured":"The PREFER Consortium. PREFER Recommendations: why, when and how to assess and use patient preferences in medical product decision-making. Accessed December 17, 2024. Available at: https:\/\/zenodo.org\/records\/6592304"},{"key":"10.1016\/j.anai.2025.12.011_bib0044","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jocm.2015.09.001","article-title":"Sample size and utility-difference precision in discrete-choice experiments: a meta-simulation approach","volume":"16","author":"Yang","year":"2015","journal-title":"J Choice Modell"},{"issue":"5","key":"10.1016\/j.anai.2025.12.011_bib0045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample size requirements for discrete-choice experiments in healthcare: a practical guide","volume":"8","author":"de Bekker-Grob","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.anai.2025.12.011_bib0046","unstructured":"World Health Organization. The World Health Organization-Five Well-Being Index (WHO-5). Accessed November 15, 2024. Available at: https:\/\/www.who.int\/publications\/m\/item\/WHO-UCN-MSD-MHE-2024.01"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s41687-023-00576-w","article-title":"Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema","volume":"7","author":"Vanya","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"10.1016\/j.anai.2025.12.011_bib0048","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-022-01167-1","article-title":"Best\u2013worst scaling and the prioritization of objects in health: a systematic review","volume":"40","author":"Hollin","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.anai.2025.12.011_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocm.2023.100466","article-title":"The rise of best-worst scaling for prioritization: a transdisciplinary literature review","volume":"50","author":"Schuster","year":"2024","journal-title":"J Choice Modell"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40271-024-00673-y","article-title":"How to present a decision object in health preference research: attributes and levels, the decision model, and the descriptive framework","volume":"18","author":"M\u00fchlbacher","year":"2025","journal-title":"Patient"},{"issue":"1150","key":"10.1016\/j.anai.2025.12.011_bib0051","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/postgradmedj-2019-137190","article-title":"Discrete choice experiment on educating value-based healthcare","volume":"97","author":"Noben","year":"2021","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0052","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4278\/0890-1171-12.1.38","article-title":"The transtheoretical model of health behavior change","volume":"12","author":"Prochaska","year":"1997","journal-title":"Am J Health Promot"},{"key":"10.1016\/j.anai.2025.12.011_bib0053","series-title":"Action Control: From Cognition to Behavior","first-page":"11","article-title":"From intentions to actions: a theory of planned behavior","author":"Ajzen","year":"1985"},{"issue":"6","key":"10.1016\/j.anai.2025.12.011_bib0054","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0272989X08326092","article-title":"A reasoned action approach to health promotion","volume":"28","author":"Fishbein","year":"2008","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bmjebm-2022-112068","article-title":"Shared decision-making as a method of care","volume":"28","author":"Montori","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.anai.2025.12.011_bib0056","unstructured":"National Institute for Health and Care Excellence (NICE). Shared decision making. Accessed November 15, 2024. Available at: https:\/\/www.nice.org.uk\/guidance\/ng197"},{"key":"10.1016\/j.anai.2025.12.011_bib0057","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. Accessed November 15, 2024. Available at: https:\/\/www.fda.gov\/media\/139088\/download"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0058","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2500\/aap.2013.34.3624","article-title":"HAE update: determining optimal patient specific therapy","volume":"34","author":"Gower","year":"2013","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0059","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2500\/aap.2018.39.4095","article-title":"Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: implications for future therapies","volume":"39","author":"Jose","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2025.12.011_bib0060","unstructured":"Center for Biologics Evaluation and Research, US Food and Drug Administration. The voice of the patient: hereditary angioedema \u2013 report of the U.S. Food and Drug Administration patient-focused drug development initiative public meeting September 2017. Accessed November 15, 2024. Available at: https:\/\/www.fda.gov\/files\/about%20fda\/published\/The-Voice-of-the-Patient---Hereditary-Angioedema.pdf."},{"issue":"1","key":"10.1016\/j.anai.2025.12.011_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12092","article-title":"Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema","volume":"12","author":"Anderson","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.12.011_bib0062","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.anai.2024.04.029","article-title":"The future of therapeutic options for hereditary angioedema","volume":"133","author":"Smith","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.12.011_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260805","article-title":"How do patients and physicians communicate about hereditary angioedema in the United States?","volume":"16","author":"Jain","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2025.12.011_bib0064","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/JAA.S284029","article-title":"Optimal management of hereditary angioedema: shared decision-making","volume":"14","author":"Banerji","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.12.011_bib0065","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.2500\/aap.2020.41.200059","article-title":"Hereditary angioedema: comprehensive management plans and patient support","volume":"41","author":"Paige","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2025.12.011_bib0066","unstructured":"The Earnest Analytics Company. Orladeyo: a tough pill to swallow for competitors in the HAE space. Accessed December 17, 2024. Available at:https:\/\/www.earnestanalytics.com\/insights\/all-posts\/orladeyo-a-tough-pill-to-swallow-for-competitors-in-the-hae-space#:\u223c:text=At%20a%20recent%20conference%2C%20BCRX,85%25%20of%20HAE%20prescription%20volume"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:30:55Z","timestamp":1772443855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625013833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1081120625013833"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.12.011","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}